Best Medicines Coalition

Recommend the creation of a Patient Ombudsman. Ensure timely access to a comprehensive range of medicines, vaccines and related treatments and protect access to clinical trials, while helping to rebuild domestic capacities to develop and make drugs and vaccines. Share patient groups perspectives on drug pricing and access to medications/vaccines/clinical trials, specifically regulations and guidelines related to the Patented Medicine Prices Review Board, along with feedback on their policies and practices, and processes related to PMPRB. Support input into the consultation on Canada Gazette, Part I, Volume 159, Number 51: Order Providing for Reliance on Decisions of, or Documents Produced by, Foreign Regulatory Authorities in Respect of Certain Drugs. Provide input on pharmacare. Ensure patient organizations are consulted and provide feedback on policies, processes, patient representation and other initiatives from Canada's Drug Agency. Recommend that the government and regulators adopt proactive approaches to communicating drug supply and shortages issues and measures to address them. Provide input on a national strategy for drugs for rare diseases. Support input regarding Canada’s pharmaceutical sovereignty. Learn more about and provide feedback on plans around COVID-19 vaccines, including protein based ones. Discuss Canada's response to the proposed bulk importation of medications from Canada to the United States. Recommend the creation of a Chief Patient Officer. Support input into the consultation on draft guidance on decentralized clinical trials. Provide input on the government's response to tariffs and other trade measures as they relate to pharmaceuticals and related treatments, including their ingredients, as well as other health products and devices. Also recommend providing financial relief to patients impacted by price increases.

Provide insight and feedback on the pharmacare program in the areas of accessibility, uses and recommendations on behalf of the coalition. Support input regarding the Pharmaceutical and Life Sciences Sector Task Force. Share patient groups perspectives on drug pricing and access to medications/vaccines/clinical trials, specifically regulations and guidelines related to the Patented Medicine Prices Review Board, along with feedback on their policies and practices, and processes related to PMPRB. Recommend that the government and regulators adopt proactive approaches to communicating drug supply and shortages issues and measures to address them. Provide input on the government's response to tariffs and other trade measures as they relate to pharmaceuticals and related treatments, including their ingredients, as well as other health products and devices. Also recommend providing financial relief to patients impacted by price increases. Provide input on a national strategy for drugs for rare diseases. Ensure timely access to a comprehensive range of medicines, vaccines and related treatments and protect access to clinical trials, while helping to rebuild domestic capacities to develop and make drugs and vaccines. Ensure patient organizations are consulted and provide feedback on policies, processes, patient representation and other initiatives from Canada's Drug Agency. Discuss Canada's response to the proposed bulk importation of medications from Canada to the United States.

Support input into the consultation on modernizing the framework for clinical trials. Support input regarding the Pharmaceutical and Life Sciences Sector Task Force. Support input regarding Canada’s pharmaceutical sovereignty. Support input into the consultation on Canada Gazette, Part I, Volume 159, Number 51: Order Providing for Reliance on Decisions of, or Documents Produced by, Foreign Regulatory Authorities in Respect of Certain Drugs. Support input into the consultation on draft guidance on decentralized clinical trials. Ensure timely access to a comprehensive range of medicines, vaccines and related treatments and protect access to clinical trials, while helping to rebuild domestic capacities to develop and make drugs and vaccines. Provide input on the government's response to tariffs and other trade measures as they relate to pharmaceuticals and related treatments, including their ingredients, as well as other health products and devices. Also recommend providing financial relief to patients impacted by price increases. Recommend the creation of a Patient Ombudsman. Recommend the creation of a Chief Patient Officer. Provide input on pharmacare. Share patient groups perspectives on drug pricing and access to medications/vaccines/clinical trials, specifically regulations and guidelines related to the Patented Medicine Prices Review Board, along with feedback on their policies and practices, and processes related to PMPRB. Recommend that the government and regulators adopt proactive approaches to communicating drug supply and shortages issues and measures to address them. Provide input on a national strategy for drugs for rare diseases. Learn more about and provide feedback on plans around COVID-19 vaccines, including protein based ones. Ensure patient organizations are consulted and provide feedback on policies, processes, patient representation and other initiatives from Canada's Drug Agency. Discuss Canada's response to the proposed bulk importation of medications from Canada to the United States.